Deferasirox Fe3 + chelating agent is a well-designed oral iron chelating agent. Its main use is to reduce chronic iron overload in patients receiving long-term blood transfusions (such as thalassemia and other chronic anemia).

Deferasirox is the first oral drug approved for this purpose in the United States. The half-life of deferasirox is between 8 and 16 hours, allowing administration once a day. The two molecules of deferasirox are able to bind to one iron atom, which is then eliminated by fecal excretion. Because of its low molecular weight and high lipophilicity, the drug can be taken orally, which is different from deferoxamine, which must be administered by intravenous injection (intravenous infusion).

554435-83-5

C21H12FeN3O4

426.18

地拉罗斯铁螯合物;Deferasirox (Fe3+ chelate)

DMSO:50 mg/mL (117.32 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years